SELECT trial information

The double-blinded SELECT cardiovascular outcomes trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular (MACE) events over a period of up to 5 years. Read more about its background, methodology, results, and more.

Filters

We are still gathering material for this library.

Please check again soon.

We're sorry

We didn't find any resources that match your selection.

Please adjust your filter(s) and try again.

SELECT trial resources

SELECT Trial Video

Obesity as a risk factor for ASCVD Video

Watch video

SELECT trial resources

SELECT Trial Video

Impact of Weight Reduction on CVD

Watch video

SELECT trial resources

SELECT Trial Video

SELECT Trial Design and Rationale

Watch video

SELECT trial resources

SELECT Trial Video

SELECT Inclusion Exclusion Criteria and Dosing

Watch video

SELECT trial resources

SELECT Trial Video

SELECT Baseline Characteristics

Watch video

SELECT trial resources

SELECT Trial Video

SELECT Primary Efficacy & Safety

Watch video

SELECT trial resources

SELECT Trial PDF

SELECT CVOT overview

Overview of SELECT CVOT trial, design, efficacy and safety results.

Download

SELECT trial resources

SELECT Trial PDF

Trial Objectives

Trial Objectives for the SELECT trial

Download

SELECT trial resources

SELECT Trial PDF

Baseline Characteristics

Baseline Characteristics for the SELECT trial

Download

Semaglutide s.c. 2.4 mg OW is not indicated for MACE risk reduction. Safety and efficacy are not established for this use under investigation. Semaglutide s.c. 2.4 mg OW is FDA-approved for chronic weight management in adults with obesity (BMI > 30), or overweight (excess weight) (BMI > 27) who also have weight-related medical problems, used with a reduced-calorie meal plan and increased physical activity. Semaglutide s.c. 2.4 mg OW is also indicated for use in patients aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex. Please see the full prescribing information for Semaglutide s.c. 2.4 mg OW here. Novo Nordisk does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Featured Insights and Resources

SELECT trial resources

SELECT Trial PDF

Trial Rationale

Trial Rationale for the SELECT trial

Download

Additional Information

Speak to a medical representative

If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.

Submit a question

Search the Medical Information Database

The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.

Begin Search

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Top